- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.12. | MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting | 173 | Business Wire | MaaT Pharma to host a KOL webinar on December 17th, 2024, to discuss data and the unmet medical need in acute Graft-versus-Host Disease (aGvHD) Register here.
Sustained High Response Rates... ► Artikel lesen | |
| 05.12. | MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease | 417 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 26.11. | MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 32 | Business Wire | MaaT033 administered for two months confirmed good safety profile and was well tolerated in patients with ALS. Other study endpoints will be analysed in the upcoming months with full data... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.11. | MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD | 365 | Business Wire | Efficacy, safety, and long-term follow-up data from 154 patients in the EAP in Europe further reinforce the excellent clinical profile of MaaT013 in GI-aGvHD.
MaaT013 is a safe and effective... ► Artikel lesen | |
| 05.11. | MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes | 259 | Business Wire | Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease; topline results expected... ► Artikel lesen | |
| 15.10. | MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease | 244 | Business Wire | Last patient treated in MaaT Pharma's Phase 3 ARES clinical trial
Topline results publication now expected in January 2025
Positive DSMB review of Phase 3 ARES trial announced in... ► Artikel lesen | |
| 19.09. | MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update | 305 | Business Wire | Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the EBMT 2024 annual meeting with 63% GI-ORR at D28, a 49% one year and 42% 18 months Overall Survival... ► Artikel lesen | |
| 09.09. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 324 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 04.09. | MaaT Pharma To Present and Participate in Investor and Medical Conferences in September | 315 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies (MET) dedicated to enhancing... ► Artikel lesen | |
| 09.08. | MaaT Pharma: MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 488 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 05.07. | MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux | 585 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 05.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 692 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07. | MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 514 | Business Wire | The Independent Data Safety and Monitoring Board (DSMB) has recommended that the trial proceed as planned without modifications. MaaT033 has shown to have an acceptable safety profile and... ► Artikel lesen | |
| 25.06. | MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 | 569 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 24.06. | MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer | 300 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 10.06. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 451 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority (AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 29.05. | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | 329 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 15.05. | MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros | 662 | Business Wire | Regulatory News:
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO... ► Artikel lesen | |
| 14.05. | MaaT Pharma Launches a Global Offering of approximately 18 Million Euros | 426 | Business Wire | Launch of an offering of new shares for approximately 17 Million Euros through a Reserved Offering aimed at categories of institutional investors, and a PrimaryBid Offering aimed at retail investors... ► Artikel lesen | |
| 07.05. | MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024 | 723 | Business Wire | Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the EBMT 2024 annual meeting with 63% GI-ORR at D28, a 49% one year and 42% 18 months Overall Survival... ► Artikel lesen |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,760 | +0,38 % | Cathie Wood's ARK buys Intellia, sells Tesla in latest stock trades | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,881 | -0,17 % | Cathie Wood's ARK buys BEAM and PACB, sells IONS stock | ||
| CENTOGENE | 0,092 | -16,36 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,210 | +4,72 % | ATAI Life Sciences N.V. - 10-Q/A, Quarterly Report | ||
| BIOMERIEUX | 100,90 | -1,08 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
| CYCLACEL | 0,300 | 0,00 % | Cyclacel stock plunges to 52-week low, hits $0.32 | ||
| SYROS PHARMACEUTICALS | 0,210 | +5,53 % | Kia Syros: Wird aus dem kleinen Verbrenner der EV1? | ||
| GENUS | 17,800 | -2,20 % | Genus Plc Expects FY25 Group Adj Profit Before Tax To Be In-line With Market View | LONDON (dpa-AFX) - Global animal genetics company Genus (GNS.L), on Tuesday, issued a trading update for the four months ending 31 October 2024 and said the Board expects Group adjusted profit... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,330 | 0,00 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 13,800 | -1,43 % | Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) | ||
| ABIONYX PHARMA | 1,180 | -0,17 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MEIRAGTX | 5,550 | +0,91 % | MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results | - Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 7,500 | -0,66 % | Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab | HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,205 | +0,24 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 8,040 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.
